Neurofilaments for NEDA Assessing in MS
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03250169|
Recruitment Status : Unknown
Verified July 2017 by Queen Mary University of London.
Recruitment status was: Recruiting
First Posted : August 15, 2017
Last Update Posted : August 15, 2017
|Condition or disease||Intervention/treatment|
|Multiple Sclerosis||Drug: Alemtuzumab|
To evaluate the achievement of NEDA using blood and CSF neurofilaments in Alemtuzumab treated patients.
- To assess prognosis at the end of the study based on neurofilament status.
- To correlate neurofilament levels with clinical and MRI markers of disease activity.
- To evaluate the effect of Alemtuzumab on the profile of other CSF, blood, urine, faeces biomarkers of inflammation, neurodegeneration, neuronal sprouting and synaptogenesis, treatment activity and metabolic activity.
|Study Type :||Observational|
|Estimated Enrollment :||60 participants|
|Official Title:||Neurofilament Heavy and Light Chain Testing for NEDA (No Evidence of Disease Activity) Assessing in Multiple Sclerosis: a Longitudinal Biomarker Study|
|Actual Study Start Date :||July 1, 2017|
|Estimated Primary Completion Date :||July 1, 2020|
|Estimated Study Completion Date :||July 1, 2020|
- Drug: Alemtuzumab
- Blood and CSF neurofilaments in Alemtuzumab patients over 24months [ Time Frame: 2 years ]Neurofilaments
- Overall clinical response based on neurofilament response [ Time Frame: 2 years ]neurofilaments
- Neurofilament status and association with clinical and MRI markers of disease activity. [ Time Frame: 2 years ]Correlation index
- Longitudinal assessment of other biomarkers of inflammation & plasticity [ Time Frame: 2 years ]Correlation index
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03250169
|Contact: Francesca Ammoscatoemail@example.com|
|Queen Mary University of London||Recruiting|
|London, England, United Kingdom, E1 2AT|
|Contact: Francesca Ammoscato firstname.lastname@example.org|